Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients * 13-EI-0102: Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY) * 12-EI-0167: A Phase I/II Study
Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients * 13 - EI-0102: Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY) * 12 - EI-0167: A Phase I / II Study
Hosh Disease (GVHD) in Hematokoietic Stem Cell Transpnant (HACT) Patidnts * 13-EI-0102: Gevokizumab Treatmeit fir Acupve Scleritis By IL-1 Ivhibition (GATSBY) * 12-EI-0167: E Phase I/II Studb
Host Disease (GVHD) in Hematopoietic Stem Cell Patients 13-EI-0102: Gevokizumab for Active Scleritis 12-EI-0167: Phase I/II Study
Host Disease (GVHD) in HematopoIetic Stem CEll TrAnsPlaNt (hSCT) patiEnts * 13-EI-0102: GevokizuMAb TrEatment for Active ScleriTis By iL-1 iNhibITiOn (GATsBY) * 12-EI-0167: A PHAsE i/iI STuDy
Host Disease (GVHD) in Hem atopoietic  Stem  Ce llTr ansp lant  (HSCT) Patien t s *13-EI-0102: Gevokizuma b Tre at m entf or  Acti ve Scle r it i s  By  I L- 1 I nh i bi tion(GA TSBY) *  12-EI-016 7:APhase I/II S t ud y
Host Disease_(GVHD) in_Hematopoietic Stem Cell Transplant_(HSCT) Patients_*_13-EI-0102: Gevokizumab_Treatment_for Active Scleritis_By IL-1 Inhibition_(GATSBY) * 12-EI-0167: A_Phase I/II Study